Physician profile
Simi Vincent
NPI 1902836620
$7,117.62
in general payments reported to CMS, 2019-2025
15 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $932 · 2021: $796 · 2022: $548 · 2023: $1,046 · 2024: $1,179 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.13 |
| Education | $270.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $2,178.55 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $908.84 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Merck Sharp & Dohme LLC | $658.23 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $537.62 | 2020-2025 | Fetroja |
| Melinta Therapeutics, LLC | $483.18 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Astellas Pharma US INC | $463.36 | 2019-2025 | Cresemba |
| La Jolla Pharmaceutical Company | $455.52 | 2021-2025 | Xacduro, Xerava, Zevtera |
| Allergan, INC. | $449.82 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $417.39 | 2019-2025 | Vibativ |
| Ferring Pharmaceuticals INC. | $183.95 | 2022-2025 | Rebyota |
| Tetraphase Pharmaceuticals, INC. | $137.48 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $133.74 | 2019-2025 | Nuzyra |
| Gilead Sciences, INC. | $71.10 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $21.02 | 2020 | |
| Nabriva Therapeutics, Plc | $17.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simi Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.